Analysis of co-receptor usage of circulating viral and proviral HIV genome quasispecies by ultra-deep pyrosequencing in patients who are candidates for CCR5 antagonist treatment

Clinical Microbiology and Infection

Volumn 17, Issue 5, 2011, Pages 725-731

  Abbate, I ^a   Rozera, G ^a   Tommasi, C ^a   Bruselles, A ^a   Bartolini, B ^a   Chillemi, G ^b   Nicastri, E ^a   Narciso, P ^a   Ippolito, G ^a   Capobianchi, M R ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b CASPUR   (Italy)

Author keywords

CCR5; Co receptor; CXCR4; HIV; Maraviroc; NGS; Pyrosequencing; Tropism; UDPS

Indexed keywords

CHEMOKINE RECEPTOR CCR5 ANTAGONIST; MARAVIROC;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; GENETIC HETEROGENEITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; PHENOTYPE; PRIORITY JOURNAL; PYROSEQUENCING; VIRUS GENOME;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79953891689     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2010.03350.x     Document Type: Article

References (25)

1. Moyle GJ, Wildfire A, Mandalia S et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005; 191: 866-872.
2. Wilkin TJ, Su Z, Kuritzkes DR et al. HIV type 1 chemokine co-receptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor. Clin Infect Dis 2007; 44: 591-595.
3. Hughes A, Nelson M. HIV entry: new insights and implications for patient management. Curr Opin Infect Dis 2009; 22: 35-42.
4. Whitcomb JM, Huang W, Fransen S et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 co-receptor tropism. Antimicrob Agents Chemother 2007; 51: 566-575.
5. Reeves JD, Coakley E, Petropoulos CJ, Whitcomb JM. An enhanced-sensitivity TrofileTM HIV co-receptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5: a review of analytical and clinical studies. J Viral Entry 2009; 3: 94-102.
6. Hung C, Heyden VN, Ratner L. Analysis of the critical domain in the V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization. J Virol 1999; 73: 8216-8226.
7. Briggs DR, Tuttle DL, Sleasman JW, Goodenow MM. Envelope V3 amino acid sequence predicts HIV-1 phenotype. AIDS 2000; 14: 2937-2955.
8. Jensen MA, Li FS, van't Wout AB et al. Improved co-receptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 2003; 77: 13376-13388.
9. Sierra S, Kaiser R, Thielen A, Lenguer T. Genotypic co-receptor analysis. Eur J Med Res 2007; 12: 453-462.
10. Rozera G, Abbate I, Bruselles A et al. Massively parallel pyrosequencing highlights minority variants in the HIV-1 env quasispecies deriving from lymphomonocyte sub-populations. Retrovirology 2009; 12: 6-15.
11. Rozera G, Abbate I, Bruselles A et al. Archived HIV-1 minority variants detected by ultra-deep pyrosequencing in provirus may be fully replication competent. AIDS 2009; 23: 2541-2543.
12. Rozera G, Abbate I, Bruselles A et al. Comparison of real-time PCR methods for measurement of HIV-1 proviral DNA. J Virol Methods 2010; 164: 135-138.
13. Cline J, Braman JC, Hogrefe HH. PCR fidelity of Pfu DNA polymerase and other thermostable DNA polymerases. Nucleic Acids Res 1996; 24: 3546-3551.
14. Vandenbroucke I, Marck HV, Mostmans W et al. HIV-1V3 envelope deep sequencing for clinical plasma specimens failing in phenotypic tropism assays. AIDS Res Ther 2010; 7: 4.
15. Beerenwinkel N, Däumer M, Oette M et al. Geno2pheno: estimating phenotypic drug resistance from HIV-1 genotypes. Nucleic Acids Res 2003; 31: 3850-3855.
16. Abbate I, Cappiello G, Longo R et al. Cell membrane proteins and quasispecies compartmentalization of CSF and plasma HIV-1 from aids patients with neurological disorders. Infect Genet Evol 2005; 5: 247-253.
17. Low AJ, Dong W, Chan D et al. Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. AIDS 2007; 21: F17-F24.
18. Skrabal K, Low AJ, Dong W et al. Determining human immunodeficiency virus co-receptor use in a clinical setting: degree of correlation between two phenotypic assays and a bioinformatic model. J Clin Microbiol 2007; 45: 279-284.
19. Westby M, Lewis M, Whitcomb J et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006; 80: 4909-4920.
20. Archer J, Braverman MS, Taillon BE et al. Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing. AIDS 2009; 23: 1209-1218.
21. Tsibris AM, Korber B, Arnaout R et al. Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS ONE 2009; 4: e5683.
22. Swenson LC, Moores A, Low AJ et al. Improved detection of CXCR4-using HIV by V3 genotyping: application of population-based and "deep" sequencing to plasma RNA and proviral DNA. J Acquir Immune Defic Syndr 2010; 54: 506-510.
23. Gulick RM, Lalezari J, Goodrich J et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359: 1429-1441.
24. Fatkenheuer G, Nelson M, Lazzarin A et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008; 359: 1442-1455.
25. Romanelli F. Maraviroc, a CCR5 co-receptor antagonist that blocks entry of human immunodeficiency virus type 1. Pharmacotherapy 2009; 29: 295-304.